3rd Midwest Cellular Therapy Conference:
Treatment Options for Advanced Hematologic Malignancies

Program Overview

Treatment options for relapsed/refractory (advanced) hematologic malignancies have progressed rapidly in only the last decade. Development of revolutionary treatment options, including CAR T-cell therapy, novel immunotherapies, and novel chemotherapeutic agents has only accelerated since the first product targeting CD19 was developed in 2003. These developments provide excellent opportunities for patients, and with opportunities arrive challenges for clinicians in maintaining optimal approaches to care. To address the educational need the 3rd Midwest Therapy Cellular Conference: Treatment Options for Advanced Hematologic Malignancies is planned .

Target Audience

This CE program is designed to meet the educational needs of hematologists, medical oncologists, pharmacists, fellows and residents, APP’s, oncology nurses and other healthcare professionals committed to the field of cellular treatment options for advanced hematologic malignancies.

Learning Objectives

Following participation in this activity, learners will:

1. Discuss individualized treatment options for high-risk patients with plasma cell diseases (multiple myeloma (MM), amyloidosis), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), Hodgkin lymphoma (HL),non-Hodgkin Lymphoma (NHL), acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML) and aplastic anemia (AA).

2. Include autologous or allogeneic HCT and/or CAR-T cell therapy in treatment plans for patients with various refractory (advanced) hematologic malignancies.

3. Manage potential complications resulting from autologous or allogeneic HCT and/or CAR-T cell therapy.

4. Utilize newer chemotherapeutic treatment options in conjunction with HCT and CAR-T cell therapy for patients with various refractory (advanced) hematologic malignancies.

Accreditation & Credit Designation

ACCREDITATION STATEMENT

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

CREDIT DESIGNATION STATEMENTS

For Physicians:

Rush University Medical Center designates this Live Activity for a maximum of 6.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn credit toward the CME of the American Board of Surgery’s Continuous Certification program.  It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting ABS credit.

For Nursing:

Rush University Medical Center designates this live activity for a maximum of 6.75 nursing contact hour(s).

For Pharmacy:

Rush University Medical Center designates this knowledge-based live activity for a maximum of 6.75 contact hour(s) for pharmacists.

Unapproved Uses of Drugs/Devices: In accordance with requirements of the FDA, the audience is advised that information presented in this continuing medical education activity may contain references to unlabeled or unapproved uses of drugs or devices. Please refer to the FDA approved package insert for each drug/device for full prescribing/utilization information.

DISCLOSURE POLICY:

It is the policy of Rush University Medical Center and the Office of Interprofessional Continuing Education to ensure that its CE activities are independent, free of commercial bias and beyond the control of persons or organizations with an economic interest in influencing the content of CE. All individuals in control of educational content must disclose all financial relationships with ineligible companies in the past 24 months. An ineligible company is an entity whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. All conflicts of interest, including potential ones, for individuals in control of educational content are mitigated prior to the planning, implementation, or evaluation of the continuing education activity.

The IPCE identifies the presence or absence of relevant financial relationships for all individuals in control of content including but not limited to planning committee members, course directors, invited presenters/authors, and staff through a standardized disclosure form. If a financial relationship is identified for the person in control of content, conflict mitigation strategies will be used to mitigate the financial relationship before they assume their role.